The historical rank and industry rank for electroCore's Gross Margin % or its related term are showing as below:
ECOR'
s Gross Margin % Range Over the Past 10 Years
Min: 36.13 Med: 51.39 Max: 82.7
Current: 82.7
During the past 8 years, the highestGross Margin % of electroCore was 82.70%. The lowest was 36.13%. And the median was 51.39%.
ECOR's Gross Margin % is ranked better than 92% of 800
companies
in the Medical Devices & Instruments industry
Industry Median: 53.135
vs ECOR: 82.70
electroCore had a gross margin of 83.69% for the quarter that ended in Mar. 2024 => Durable competitive advantage
The 5-Year average Growth Rate of Gross Margin for electroCore was 15.90% per year.
electroCore Gross Margin % Historical Data
The historical data trend for electroCore's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of electroCore's Gross Margin %
For the Medical Devices subindustry, electroCore's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
electroCore's Gross Margin % Distribution in the Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, electroCore's Gross Margin % distribution charts can be found below:
* The bar in red indicates where electroCore's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
electroCore (NAS:ECOR) Gross Margin % Explanation
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
electroCore had a gross margin of 83.69% for the quarter that ended in Mar. 2024 => Durable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
electroCore Gross Margin % Related Terms
Thank you for viewing the detailed overview of electroCore's Gross Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.
electroCore Inc is a commercial stage bioelectronic medicine company with a platform for non-invasive vagus nerve stimulation therapy initially focused on neurology. The company's product gammaCore is Food and Drug Administration cleared in the United States for adjunctive use for the preventive treatment of cluster headache in adult patients, the acute treatment of pain associated with episodic cluster headache in adult patients, the acute treatment of pain associated with migraine headache in adult patients and the prevention of migraine in adult patients. The gammaCore is CE-marked in the European Union for the acute and/or prophylactic treatment of primary headache, Bronchoconstriction and Medication Overuse Headache in adults.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
ECOR has been successfully added to your 